Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 48

1.

The imaging core lab perspective on glioblastoma imaging and response assessment in clinical trials.

Goldmacher GV, Raunig D.

Neuro Oncol. 2014 Oct;16 Suppl 7:vii48-50. doi: 10.1093/neuonc/nou225.

PMID:
25313238
2.

Antiplatelet therapy for secondary prevention of coronary artery disease.

Pilgrim T, Windecker S.

Heart. 2014 Nov;100(22):1750-6. doi: 10.1136/heartjnl-2013-305399. Epub 2014 Jul 18. Review.

PMID:
25037531
3.

Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B, Alcaraz A, Bahl A, Bracarda S, Di Lorenzo G, Efstathiou E, Finn SP, Fosså S, Gillessen S, Kellokumpu-Lehtinen PL, Lecouvet FE, Oudard S, de Reijke TM, Robson CN, De Santis M, Seruga B, de Wit R.

Eur J Cancer. 2014 Jun;50(9):1617-27. doi: 10.1016/j.ejca.2014.03.010. Epub 2014 Apr 3.

4.

Radiation therapy for retroperitoneal sarcoma.

Tuan J, Vitolo V, Vischioni B, Iannalfi A, Fiore MR, Fossati P, Orecchia R.

Radiol Med. 2014 Oct;119(10):790-802. doi: 10.1007/s11547-013-0350-3. Epub 2014 Mar 18. Review.

PMID:
24638910
5.

Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.

León L, García-Figueiras R, Suárez C, Arjonilla A, Puente J, Vargas B, Méndez Vidal MJ, Sebastiá C.

Target Oncol. 2014 Mar;9(1):9-24. doi: 10.1007/s11523-013-0304-7. Epub 2013 Dec 12. Review. Erratum in: Target Oncol. 2014 Jun;9(2):181. García-Figueras, Roberto [corrected to García-Figueiras, Roberto].

PMID:
24338498
7.

Good outcome rate of 35% in IV-tPA-treated patients with computed tomography angiography confirmed severe anterior circulation occlusive stroke.

González RG, Furie KL, Goldmacher GV, Smith WS, Kamalian S, Payabvash S, Harris GJ, Halpern EF, Koroshetz WJ, Camargo EC, Dillon WP, Lev MH.

Stroke. 2013 Nov;44(11):3109-13. doi: 10.1161/STROKEAHA.113.001938. Epub 2013 Sep 3.

8.

Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.

Galsky MD, Xie W, Nakabayashi M, Ross RW, Fennessy FM, Tempany CM, Choueiri TK, Khine K, Kantoff PW, Taplin ME, Oh WK.

Prostate Cancer Prostatic Dis. 2013 Sep;16(3):266-70. doi: 10.1038/pcan.2013.15. Epub 2013 May 28.

9.

Tracking transplanted bone marrow stem cells and their effects in the rat MCAO stroke model.

Goldmacher GV, Nasser R, Lee DY, Yigit S, Rosenwasser R, Iacovitti L.

PLoS One. 2013;8(3):e60049. doi: 10.1371/journal.pone.0060049. Epub 2013 Mar 29.

10.

Dose escalation for locally advanced lung cancer using adaptive radiation therapy with simultaneous integrated volume-adapted boost.

Weiss E, Fatyga M, Wu Y, Dogan N, Balik S, Sleeman W 4th, Hugo G.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):414-9. doi: 10.1016/j.ijrobp.2012.12.027. Epub 2013 Mar 21.

11.

Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase.

Szlosarek PW, Luong P, Phillips MM, Baccarini M, Stephen E, Szyszko T, Sheaff MT, Avril N.

J Clin Oncol. 2013 Mar 1;31(7):e111-3. doi: 10.1200/JCO.2012.42.1784. Epub 2013 Jan 14. No abstract available.

12.

Single-scan dual-tracer FLT+FDG PET tumor characterization.

Kadrmas DJ, Rust TC, Hoffman JM.

Phys Med Biol. 2013 Feb 7;58(3):429-49. doi: 10.1088/0031-9155/58/3/429. Epub 2013 Jan 8.

13.

Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography.

Lordick F.

Recent Results Cancer Res. 2012;196:201-11. doi: 10.1007/978-3-642-31629-6_14. Review.

PMID:
23129376
14.

Management of salivary gland tumors.

Andry G, Hamoir M, Locati LD, Licitra L, Langendijk JA.

Expert Rev Anticancer Ther. 2012 Sep;12(9):1161-8. doi: 10.1586/era.12.92. Review.

PMID:
23098116
15.

Selection of possible responders to thrombolytic therapy in acute ischemic stroke.

Hametner C, Ringleb PA, Hacke W, Kellert L.

Ann N Y Acad Sci. 2012 Sep;1268:120-6. doi: 10.1111/j.1749-6632.2012.06747.x. Review.

PMID:
22994230
16.

Pulmonary embolism: risk assessment and management.

Konstantinides S, Goldhaber SZ.

Eur Heart J. 2012 Dec;33(24):3014-22. doi: 10.1093/eurheartj/ehs258. Epub 2012 Sep 7. Review.

17.

Promise and pitfalls of quantitative imaging in oncology clinical trials.

Kurland BF, Gerstner ER, Mountz JM, Schwartz LH, Ryan CW, Graham MM, Buatti JM, Fennessy FM, Eikman EA, Kumar V, Forster KM, Wahl RL, Lieberman FS.

Magn Reson Imaging. 2012 Nov;30(9):1301-12. doi: 10.1016/j.mri.2012.06.009. Epub 2012 Aug 13. Review.

18.

A new manganese-based oral contrast agent (CMC-001) for liver MRI: pharmacological and pharmaceutical aspects.

Jørgensen JT, Rief M, Brismar TB, Wagner M, Albiin N.

Acta Radiol. 2012 Sep 1;53(7):707-13. doi: 10.1258/ar.2012.120034. Epub 2012 Jul 20. Review.

PMID:
22821959
19.

Management of advanced genitourinary tumors.

Pietrantonio F, Biondani P, Verzoni E, Procopio G.

Tumori. 2012 Mar-Apr;98(2):264-6. doi: 10.1700/1088.11940.

PMID:
22677995
20.

Positron emission tomographic scans in lymphoma: convention and controversy.

Ansell SM, Armitage JO.

Mayo Clin Proc. 2012 Jun;87(6):571-80. doi: 10.1016/j.mayocp.2012.03.006. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk